Radiomic and dosiomic machine learning models for predicting radiation-induced oral mucositis in head and neck cancer: a systematic review.

Clin Transl OncolJun 8, 2026 (epub)
Clinical ResearchOncology (Medical)Open access

Lukas Mendes de Abreu, Raquel Molina Sanches, Alana Crescencio de Oliveira et al.

✦ AI-curated · Sources linked

In 30 seconds

This PRISMA-guided systematic review assessed machine-learning models using radiomic and/or dosiomic data to predict radiation-induced oral mucositis in patients with head and neck cancer. Seven studies involving 2,311 patients were included; all models used dosimetric predictors, with some adding other imaging features or oral health indices. Reported discrimination ranged from AUC 0.70 to 0.96, while external validations showed reduced performance (AUC ~ 0.65). The review identified high risk of bias, particularly in analysis, and concluded that these models remain exploratory rather than ready for routine clinical use.

Key findings

  • Seven studies involving 2,311 patients were included, and all models incorporated dosimetric predictors.
  • Reported AUC ranged from 0.70 to 0.96; external validations showed reduced performance (AUC ~ 0.65).
  • High risk of bias was mainly identified in analysis domains, associated with limited sample sizes and incomplete calibration.

Why it matters

Predicting oral mucositis could help characterize risk during radiotherapy, but model performance in development studies may not translate to other settings. The reduced discrimination in external validation and concerns about calibration and bias indicate that reported accuracy should be interpreted cautiously before these tools inform clinical decisions.

What to keep in mind

The review found limited sample sizes and incomplete calibration, with high risk of bias mainly in analysis domains; external validation performance was reduced.

Source

Published in Clin Transl Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.